LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Inhibition of histone deacetylase (HDAC) provides a novel approach for cancer treatment.
LBH589, an oral HDAC inhibitor, has been well tolerated in phase I trials and has shown
activity against several types of cancer. In this nonrandomized phase II trial, we are
investigating the activity of LBH589 in the treatment of patients with refractory clear cell
renal carcinoma.